Institute of Tropical Medicine
Tübingen, Deutschland, 72074, Germany
NCT Number: NCT04581889
This is a prospective, longitudinal study to determine the incidence of SARS-COV-2 infection in children and adolescents by measuring specific antibodies in non-invasive saliva sampled in kindergartens and schools in a defined city area. The study includes an additional arm to validate the ELISA for anti-SARS-COV-2 reactive antibody measurements in saliva compared against blood collected in adult volunteers in a bimonthly follow-up period for 12 months.
Looking for future studies?
Notify Me1 year–18 year
All sexes
Observational
Tübingen, Deutschland, 72074, Germany
The world is confronting Coronavirus Disease-2019 (COVID-19) pandemic caused by SARS-CoV-2 virus, which is causing many deaths and burden on intensive care facilities. Data regarding epidemiologic characteristics in children and young adults is limited, especially in the context of educational settings. Due to mild symptoms or even asymptomatic cases in children, the rate of SARS-CoV-2 infected children is underestimated. Therefore, the present study aims to determine the incidence of SARS-CoV-2 infection in children at 3 timepoints during 12 months expressed as seroconversion measured in non-invasive saliva sampling in Tübingen, a defined study area. Children and adolescents (N = 1850) in the age of 1 to 17 years will be recruited via child-care, kindergarten and primary and secondary schools and followed-up for 12 months: shortly after release of lock-down measures in summer 2020, before winter and after the winter. An adult cohort (adult comparator group) is sampled at the same time points for incidence comparisons. To validate the ELISA for SARS-CoV-2 antibody measurements in saliva compared to blood, and to understand the half-life of SARS-CoV-2 antibodies in respective body fluids, peripheral blood and in saliva will be sampled every 2 months in an additional adult group (adult validation group).
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Adult population:
Exclusion criteria
Presence of antibodies in saliva
Time frame: 12 months
Identification of children that have been infected over different periods of time (summer, before winter and after winter) based on saliva samples
Time frame: 12 months
Change of incidence of SARS-CoV-2 infection in children during 2020/2021
Time frame: 12 months
SARS-CoV-2 antibodies persistence in peripheral blood and saliva
Time frame: 18 months
Saliva samples as alternative for the detection of antibodies against SARS-CoV-2
University Hospital Tuebingen
Other
Prospective, Seroepidemiological, Non-invasive Cohort Study in Tübingen Children Age-stratified by Nursery and School Attendance
Acronym: Coro-Buddy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04839146
COVID-19, Coronaviridae Infections
Nijmegen, Gelderland, Netherlands
View Trial DetailsNCT04366934
Anosmia, Coronaviridae Infections
Paris, France
View Trial DetailsNCT04402957
Acute Kidney Injury, Acute Respiratory Distress Syndrome
San Diego, California, United States
View Trial DetailsNCT04527432
Coronaviridae Infections, Coronavirus Infection
Wolverhampton, United Kingdom
View Trial Details